Compare Inovio Pharmaceuticals Inc (INO) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Open Text Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Open Text Corporation trades at $23.52 (market cap $5.80B). The key difference: Open Text Corporation is far larger — about 73.8× Inovio Pharmaceuticals Inc's market cap, and Open Text Corporation pays a 4.67% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | OTEX | |
|---|---|---|
Market Cap | $78.55M | $5.80B |
Sector | Health | Technology |
52-Week High | $2.87 | $39.69 |
52-Week Low | $0.66 | $20.01 |
Enterprise Value | $49.56M | $10.81B |
Dividend Yield | — | 4.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Open Text Corporation (OTEX) trades at $23.27, down 5.87% over the past day, with a bullish technical signal despite recent weakness. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.23 versus $1.02 expected, and maintains solid fundamentals including a 73.74% gross margin and 12.26% net income margin. Recent news highlights cloud revenue growth and a $105 million AI investment in Europe.
Outlook remains positive with a consensus price target of $29.33 implying 26% upside, supported by earnings beats and strategic AI investments. Risks include high debt levels and competitive pressures in the software sector. The stock offers value with a P/E of 9.29 and a 4.7% dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
